Delayed administration of elezanumab, a human anti-RGMa neutralizing monoclonal antibody, promotes recovery following cervical spinal cord injury
2022 · Neurobiology of Disease · 21 citations
https://doi.org/10.1016/j.nbd.2022.105812
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
4
Papers
63
Citations
3
h-index
3
i10-index
Mitchell T. Caprelli is an academic researcher from University Health Network. The author has contributed to research in topics: Traumatic Brain Injury Research & Traumatic Brain Injury and Neurovascular Disturbances & Spinal Cord Injury Research. The author has an h-index of 3, co-authored 4 publications.
Click to start Chat